“…Twenty-one studies (28 patient groups) in 17,863 COVID-19 patients (60% males, mean age 66 years), all retrospective, reported sensitivity and specificity of the ability of the SII to predict severe disease or mortality ( 36 – 40 , 42 , 45 , 47 , 48 , 51 , 53 , 54 , 56 , 58 , 61 , 64 , 68 – 70 , 72 , 74 ). Twelve studies were performed in Asia ( 36 , 38 , 40 , 42 , 48 , 51 , 54 , 64 , 68 , 70 , 72 , 74 ), six in Europe ( 39 , 47 , 56 , 58 , 61 , 69 ), two in America ( 37 , 45 ), and one in Africa ( 53 ). The studied endpoint was mortality in 12 studies ( 36 , 37 , 39 , 45 , 47 , 48 , 51 , 54 , 56 , 58 , 61 , 68 ), ICU admission in seven ( 38 – 40 , 45 , 53 , 68 , 69 ), disease severity based on existing guidelines in five ( 42 , 64 , 70 , 72 , 74 ), acute pulmonary embolism in one ( 61 ), acute limb ischemia in one ( ...…”